Edition:
United States

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

9.50EUR
11:35am EDT
Change (% chg)

€0.15 (+1.60%)
Prev Close
€9.35
Open
€9.35
Day's High
€9.50
Day's Low
€9.30
Volume
244,750
Avg. Vol
562,681
52-wk High
€16.88
52-wk Low
€7.85

Select another date:

Thu, Sep 7 2017

BRIEF-Almirall announces phase III positive Duaklir results for COPD

* SAYS PHASE III STUDY SHOWS DUAKLIR SIGNIFICANTLY IMPROVES LUNG FUNCTION IN MODERATE TO VERY SEVERE STABLE COPD

BRIEF-Almirall board approves appointment of Peter Guenter as new CEO

* BOARD APPROVES APPOINTMENT OF PETER GUENTER AS CEO EFFECTIVE OCT. 1 FOLLOWING SUCCESSION PLAN INITIATED MORE THAN A YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Almirall appoints Ron Menezes as President and General Manager of Aqua Pharmaceuticals

* NAMES RON MENEZES AS PRESIDENT AND GENERAL MANAGER OF AQUA PHARMACEUTICALS Further company coverage: (Gdynia Newsroom)

BRIEF-Almirall H1 EBITDA down 52.6 pct at 58.6 mln euros YoY

* H1 EBITDA DOWN 52.6 PERCENT AT 58.6 MILLION EUROS VERSUS YEAR AGO

BRIEF-Almirall H1 net result turns to loss of 73.1 mln euros

* H1 NET LOSS 73.1 MILLION EUROS VERSUS PROFIT 80.5 MILLION EUROS YEAR AGO

BRIEF-Almirall reduces FY 2017 revenue, net sales and EBITDA growth estimates

* PROVIDES UPDATE TO FY 2017 GUIDANCE THAT REDUCES INITIAL ESTIMATIONS FOR TOTAL REVENUES, NET SALES AND EBITDA GROWTH

BRIEF-Almirall says EC approves its Skilarence drug for chronic plaque psoriasis

* EUROPEAN COMMISSION (EC) APPROVES ALMIRALL'S SKILARENCE FOR MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS

BRIEF-Almirall is ready with authorized generic of Acticlate to be introduced to US market‍​

* SAYS IT IS READY WITH AN AUTHORIZED GENERIC (AG) OF ACTICLATE TO BE INTRODUCED TO THE US MARKET‍​

BRIEF-Almirall and Leo Pharma to collaborate on minimally invasive skin sampling method

* ALMIRALL AND LEO PHARMA TO COLLABORATE ON DEVELOPING AND CLINICALLY VALIDATING MINIMALLY INVASIVE SKIN SAMPLING METHOD Further company coverage: (Gdynia Newsroom)

BRIEF-Almirall Q1 net profit down at 19.6 mln euros

* Q1 EBITDA 55.0 MILLION EUROS ($60.4 MILLION) VERSUS 54.8 MILLION EUROS YEAR AGO

Select another date: